From plant resin and honeybee venom to apoptosis and autophagy, research is tracing how bee-associated chemistry interacts with the machinery of cancer cells.What propolis, bee venom and cancer research are revealing about apoptosis, autophagy and the living chemistry connecting plants, bees and us
At a glance: This article follows the chemistry of the hive from plant resin transformed into propolis, to melittin produced inside the honeybee, to honey itself. Across laboratory, animal and emerging clinical research, these bee-associated substances are being studied for their effects on some of the same biological processes that matter in cancer, including apoptosis, autophagy, cell signalling, inflammation, treatment response and the survival of abnormal cells. Much of the anticancer evidence remains preclinical, but the research is increasingly detailed and points to something larger than any single compound: a living chemistry that moves from plants, through bees and the hive, and into biological systems far beyond them…
A honeybee lands on a resinous plant, often a tree or shrub, not for nectar or pollen, but for resin.
From a bud, a wound, a stem or another resinous surface, she gathers part of the plant’s own chemical defence and carries it home.
Inside the colony, that plant resin becomes part of something else. Mixed and worked by bees, it becomes propolis, spread through cracks, rough surfaces and the inner walls of the nest.
For the plant, resin is defence.
For the bee, it becomes defence again.
And there is another kind of defence inside the bee herself.
Honeybee venom contains melittin, a small peptide evolved for an entirely different purpose.
One begins with a plant.
The other begins with a bee.
And both are now turning up under microscopes in cancer laboratories.
That may be one of the most extraordinary things about this research.
It reminds us that nature does not always draw the boundaries we do.
Plant.
Bee.
Hive.
Microbe.
Cell.
Human.
We give them separate names.
Chemistry keeps moving between them.
The hive has walls that are alive with chemistry
Wild honeybees nesting inside tree cavities often coat the rough interior surfaces with a continuous layer of propolis.
Researchers call it the propolis envelope.
It is not simply caulking.
A 2024 study found that rough hive boxes stimulated bees to deposit substantially more propolis than smooth conventional boxes. Colonies with greater propolis deposition showed evidence consistent with improved hive homeostasis, including lower detection of Melissococcus plutonius (the bacterium that causes European foulbrood) in rough boxes, tendencies toward lower viral loads as propolis increased, and stabilization or seasonal reduction of several immune and bacterial gene-expression measures.
That matters because an immune system costs energy.
Bees do not simply store propolis. They build it into the colony around them. In this 2024 experiment, roughened hive walls stimulated substantially more propolis deposition than conventional smooth wooden boxes, helping restore something closer to the propolis-rich interior of a natural tree cavity.If the environment around an animal helps suppress microbial threats, the animal may not have to mount the same internal response constantly.
In a honeybee colony, part of immunity may therefore exist outside the individual bee.
It can exist in the walls.
That is social immunity.
The colony alters its surroundings, and those surroundings help protect the colony.
There is something profound in that.
We tend to imagine medicine as something administered after sickness arrives.
Bees remind us that health can also be built into the environment itself.
Then researchers began looking beyond the hive
In 2025, researchers published a major review of propolis in animal models of cancer and infectious disease.
They screened 222 scientific records published between 2010 and 2025, focusing specifically on in vivo research rather than simply cells growing in a dish.
Across those animal studies, propolis repeatedly showed biological activity against tumors and infectious organisms.
In cancer models, researchers reported effects involving cancer-cell proliferation, angiogenesis, metastasis, immune signalling and apoptosis.
A broader 2021 review of propolis and cancer research paints an even wider picture, including proliferation, angiogenesis, metastasis, the tumor microenvironment, multidrug resistance, autophagy and, again and again, apoptosis.
Cancer survives by breaking more than one rule.
It keeps dividing when it should stop. It can resist signals telling damaged cells to die. It can recruit blood vessels, invade neighbouring tissue, alter its surroundings and develop resistance to treatment.
That is why these mechanisms matter.
Apoptosis
Cancer is, in part, a disease of cells refusing instructions they once obeyed.
Healthy multicellular life depends on cells knowing not only how to live, but when to die.
Apoptosis is programmed cell death.
It is one of biology’s ways of removing damaged, dangerous or no-longer-needed cells without simply allowing them to continue multiplying.
Cancer cells often acquire ways of resisting that process.
That is why apoptosis matters so much in cancer biology.
Apoptosis is not a single switch. It is controlled by interconnected molecular pathways. Experimental research has found that propolis and several of its constituent compounds can influence both intrinsic and extrinsic signalling involved in programmed cell death.Across the animal studies examined in the 2025 propolis review, induction of apoptosis appeared repeatedly as one of propolis’s principal anticancer effects. The review describes pro-apoptotic activity in breast, cervical, gastrointestinal and other tumor models, together with reduced tumor growth and changes in pathways governing cell survival and proliferation.
Some propolis preparations have also shown preferential effects on cancer cells over normal cells in laboratory studies, although that selectivity is not universal and depends strongly on the propolis source, extract, dose and cell type.
And the story is no longer confined to broad reviews.
A recent Scientific Reports study examined propolis from five stingless-bee species in Brunei against lymphoma, lung and bladder cancer cells. Some lymphoma cells were particularly sensitive to the extracts, while molecular analysis found changes in pathways involved in cell-cycle progression and cancer signalling, including E2F, G2M-checkpoint and mTORC1 activity.
Different bees.
Different plants.
Different propolis.
Different chemistry.
Yet once again, researchers found themselves looking deep inside the machinery governing whether cancer cells continue growing.
Think about what that means for a moment.
A bee collects resin from a plant.
That resin contains compounds produced through millions of years of plant evolution.
The bee incorporates those compounds into the defensive chemistry of a colony.
And when scientists later expose mammalian biological systems to propolis preparations, some of the molecular responses they observe involve machinery governing whether damaged cells continue living or enter apoptosis.
That is what makes this research so compelling.
The chemistry bees gather from plants is showing the ability in experimental cancer models to interfere with the very cellular machinery cancer cells use to survive, proliferate, spread and resist death. Scientists are not looking at propolis because of folklore. They are looking because measurable biological effects keep appearing.
And apoptosis is not the only cellular process appearing in that research.
Autophagy
There is another word that belongs in this story:
autophagy.
The word literally refers to cells consuming parts of themselves.
But autophagy is not simply cellular destruction.
It is recycling.
Cells dismantle damaged proteins and worn-out components, recover useful material and reorganize themselves in response to stress.
It is an ancient survival system.
In cancer research, autophagy matters because it sits at the heart of how cells respond to stress. Researchers are studying how altering that recycling system can strip cancer cells of survival advantages and, in some settings, help push them toward growth arrest and death.
One 2025 study looked directly at water-based propolis combined with 5-fluorouracil, a chemotherapy drug used against gastrointestinal cancers.
Researchers tested the combination against gastric and colorectal cancer cells.
The propolis increased the effectiveness of 5-FU, reducing the concentration required to inhibit the cancer cells, while also reducing 5-FU toxicity in the non-cancerous cells used for comparison.
In that experimental model, propolis was not simply adding more toxicity. It appeared to widen the difference between the treatment’s effect on cancer cells and its effect on non-cancerous cells.
Then the researchers looked inside the cells.
The combination increased reactive oxygen species, disrupted mitochondrial membrane potential, produced endoplasmic-reticulum stress and increased AUTOPHAGY.
The cells entered cell-cycle arrest.
And then came APOPTOSIS.
The effects appeared in both a cancer-cell line with functioning p53 and another lacking it.
There they are together.
AUTOPHAGY.
APOPTOSIS.
Two of the most fundamental cellular processes shaping whether a cancer cell survives, adapts or dies are appearing together in research involving a substance bees make from the chemistry of plants.
That is not mythology. It is measurable biology.
And it is one reason propolis continues to be investigated for its anticancer potential, both on its own and alongside existing cancer treatments.
Propolis may also change how another treatment works
That may become one of the most important themes in this research.
The question is not only:
Can propolis act against cancer?
It is also:
Can propolis change how cancer responds to treatment?
The 2025 preclinical review found animal studies in which propolis was investigated alongside 5-fluorouracil, methotrexate, irinotecan, cisplatin and other cancer treatments.
Some experiments reported stronger antitumor effects from combinations. Others examined whether propolis could reduce treatment-related injury.
Those studies included models involving 5-FU-related heart injury, cisplatin-related kidney injury, irinotecan-related blood, liver and kidney toxicity, doxorubicin-related liver and reproductive injury, cyclophosphamide-related blood, liver and kidney injury, and mitomycin-related genetic and reproductive damage.
Radiation research has also examined osteoradionecrosis, oral mucositis and salivary-gland injury.
A separate review of full-spectrum propolis and pharmaceutical drugs found positive or synergistic interactions with several chemotherapy drugs, including enhanced antitumor activity, effects on chemoresistant cancer cells and reductions in treatment-related toxicity in preclinical research.
That changes the shape of the question again.
A substance does not necessarily have to replace a cancer treatment to matter.
Its importance may also lie in whether it can help an existing treatment work better, alter resistance or help protect healthy tissue while cancer is being treated.
And then there is the venom
The propolis story begins largely with plants.
The venom story begins inside the bee.
Melittin is a major peptide in honeybee venom, and it has become one of the most intensively studied bee-derived molecules in experimental cancer research.
A particularly striking 2020 study examined honeybee venom and melittin in aggressive forms of breast cancer.
Researchers found strong activity against triple-negative and HER2-enriched breast cancer cells.
Melittin interfered with activation of EGFR and HER2, growth-factor receptors involved in signalling in these cancers.
In the same study, that effect was not evenly distributed across every cell type. Honeybee venom and melittin were significantly more potent against triple-negative and HER2-enriched breast-cancer cells than against the nontransformed cells used for comparison. The researchers described the response as highly selective, and further engineered melittin to improve malignant-cell targeting while minimizing toxicity to normal cells.
Honey bee venom and melittin produced measurable apoptotic and membrane-disrupting effects in aggressive breast-cancer cells in a 2020 study. The researchers also found that melittin interfered with EGFR and HER2 signalling.The researchers also modified melittin to improve malignant-cell targeting, and in an animal tumor model melittin enhanced the tumor-suppressing effect of docetaxel.
That is a very different kind of bee medicine.
Propolis is largely gathered.
Melittin is made by the bee herself.
But both stories arrive at the same extraordinary place:
the machinery of cancer cells.
APOPTOSIS appears again
A 2025 review of melittin-based nanomedicine across 18 cancer types describes anticancer activity involving direct membrane disruption, suppression of cancer-driving signalling and mitochondrial APOPTOSIS.
That includes mechanisms involving reactive oxygen species, mitochondrial disruption and cytochrome-c release.
Researchers are also trying to solve melittin’s biggest problem.
Free melittin can damage normal cells, particularly red blood cells.
So scientists are packaging it inside liposomes, polymer particles, micelles, dendrimers and other delivery systems designed to concentrate its activity at tumors while reducing damage elsewhere.
The cancer map in that research is remarkable.
Breast cancer. Melanoma. Liver cancer. Ovarian cancer. Colorectal cancer. Prostate cancer. Pancreatic cancer. Lung cancer. Glioblastoma. Osteosarcoma. Leukemia. Lymphoma. Gastric cancer. Cervical cancer. Bladder cancer. Thyroid cancer. Head-and-neck cancer. Esophageal cancer. Endometrial cancer.
This is no longer one unusual experiment involving one cancer cell line.
It has become an entire field of research into how a peptide produced by a honeybee might be directed against cancer.
Breast cancer keeps bringing us back to the bee
A 2026 review focused specifically on venom-derived peptides in breast cancer expands that picture further.
The research includes triple-negative, HER2-positive and hormone-receptor-positive breast-cancer models.
The mechanisms researchers are studying include APOPTOSIS, cell-cycle arrest, inhibition of angiogenesis, membrane disruption, immune modulation and interference with cancer-driving signalling pathways.
For bee-derived melittin specifically, the review describes effects involving PI3K/Akt/mTOR, NF-κB and HIF-1α signalling, along with migration, invasion, metastasis and activation of apoptotic pathways.
The molecule evolved as part of a bee’s defence.
Humans are now studying how that same molecule can interfere with the survival machinery of breast cancer cells. And researchers are now beginning to watch that transition unfold in remarkable molecular detail. A 2026 study exposed MDA-MB-231 triple-negative breast-cancer cells to melittin at different concentrations and followed their proteome over time, measuring roughly 5,800 proteins. At the lower exposure, the cells initially showed an adaptive stress response. At the higher exposure, that response shifted toward increasingly severe cellular disruption and apoptotic collapse. Instead of seeing only the end result, researchers were beginning to map the molecular journey from a cancer cell attempting to survive melittin exposure to one moving toward programmed death.
And propolis research keeps moving too
Even in 2026 researchers are still finding different ways to investigate it.
A Malaysian study tested propolis extracts against MDA-MB-231 triple-negative breast cancer cells.
Both ethanol and acetone extracts reduced cancer-cell viability in a concentration-dependent way.
Researchers then used the propolis extracts in the green synthesis of silver nanoparticles.
Those propolis-mediated nanoparticles showed stronger anticancer activity than the original extracts in that cell model.
The same study also found antibacterial activity against Bacillus cereus with the acetone extract, while Enterococcus faecalis did not respond under the conditions tested.
There is something useful in that distinction too.
Natural chemistry is not simply an on-off switch that acts against everything.
Its effects depend on the organism, the compounds, their concentrations, their combinations and the biological system they encounter.
And that brings us back to something propolis has been showing us throughout this story:
complexity matters.
The same substance appears in battles against infection
The story becomes even wider.
The 2025 review also examined animal studies involving bacteria, fungi, parasites and viruses.
Across those models, propolis preparations were associated with reduced pathogen burdens, altered inflammatory responses, reduced tissue damage and modulation of host immunity.
Researchers reported activity involving organisms including Staphylococcus aureus, Salmonella, Candida albicans, Cryptococcus, Toxoplasma, Leishmania, herpes viruses and influenza A.
That research is still moving forward.
In September 2026, researchers studying a standardized Apis mellifera propolis extract in experimental Schistosoma mansoni infection reported reduced parasite egg burden, granulomatous inflammation and liver fibrosis in infected mice, alongside effects on parasite viability and inflammatory signalling.
Taken together, the review concluded that propolis showed consistent anticancer and antimicrobial effects in animal models.
What we sometimes scrape from equipment and complain about because it sticks everything together is part of a chemical defence system that the colony has been constructing around itself all along.
The medicine begins before the bee
But perhaps the most interesting part of this story is that propolis does not truly begin with bees.
It begins with plants.
Plants cannot run from infection.
They cannot move away from an insect chewing their tissues.
They cannot walk into another climate when conditions become hostile.
So plants became chemists.
Across evolutionary time they developed immense libraries of molecules involved in signalling, defence, wound response, microbial control and interaction with other organisms.
Bees enter that chemistry.
They find defensive plant chemistry in the landscape, collect it, transport it, mix it and incorporate it into another living system.
A defence produced by one organism becomes part of the defence of another.
The plant protects itself.
The bee carries part of that protection home.
The colony builds it into its walls.
And humans eventually carry samples of those walls into laboratories and discover effects involving microbes, inflammation, apoptosis, autophagy, angiogenesis and immune signalling.
There is no straight line anymore.
There is a web.
Honey is another strand in that web
There is another substance in this story that is so familiar we can almost fail to see how extraordinary it is.
Honey.
Propolis begins largely with resin.
Honey begins with flowers.
A plant makes nectar. A bee gathers it, carries it inside herself, alters it with enzymes, passes it through the colony and concentrates it until something that began in a flower becomes something new inside the hive.
And researchers have been following that chemistry into cancer biology for years.
More than a decade ago, reviews of experimental honey research were already describing effects involving cell proliferation, inflammation, oxidative signalling and apoptosis.
That last word should sound familiar by now.
Studies examined changes in some of the same molecular machinery appearing throughout this story: caspases involved in programmed cell death, the tumor-suppressor protein p53, the pro-apoptotic protein Bax, and Bcl-2, a protein that can help cells resist death.
In 2015, a review devoted specifically to the antiproliferative and apoptotic activity of natural honey gathered evidence from cancer-cell experiments and animal models and argued that the subject warranted substantially more preclinical and clinical investigation.
The remarkable thing is that the question did not go away.
It grew.
A 2026 review in Frontiers in Oncology returned to honey and cancer with a much larger body of research behind it. Once again, researchers were looking at caspase-mediated apoptosis and cell-cycle control, but also at NF-κB and STAT3 signalling, metastasis-related mechanisms and whether honey might alter the response of tumors to chemotherapy.
A scientific question asked years ago was still alive.
And it had moved forward.
And one 2026 study added something especially interesting: selectivity. Chestnut-honey mixtures fortified with bee products selectively triggered apoptosis in the cancer cells without producing the same apoptotic response in the normal cells. The strongest effect came from chestnut honey enriched with 10% propolis and 10% royal jelly. That result applies to the tested fortified mixture, not to honey in general, but it adds another intriguing example of researchers looking not only for anticancer activity, but for selectivity between cancerous and healthy cells.
But honey brings something else into this story too.
Much of the anticancer evidence surrounding propolis and melittin remains preclinical. Honey has also crossed into research involving people receiving cancer treatment.
One of the clearest examples is oral mucositis, the severe inflammation and ulceration that can develop in the mouth during cancer therapy, particularly radiotherapy for cancers of the head and neck.
A 2025 overview examined 12 systematic reviews of honey for cancer-treatment-induced oral mucositis. Several of the higher-quality reviews consistently found that honey reduced the occurrence of severe radiation-induced oral mucositis, and some evidence suggested less severe pain and fewer interruptions to treatment.
That does not mean honey has been proven to treat cancer itself.
It means something different, and scientifically important.
The same substance is being investigated at two very different scales.
At one scale, researchers expose cancer cells to honey and watch signalling pathways, proliferation and programmed cell death.
At another, researchers give honey to people undergoing cancer treatment and ask whether it can help protect damaged tissue.
Follow either path backward and eventually we arrive at something almost absurdly ordinary.
A flower.
A bee.
A drop of nectar.
Perhaps that is what makes the chemistry of the hive so easy to underestimate.
We see honey and think sweetness.
The bee sees food.
The colony sees stored energy.
The chemist sees sugars, enzymes, organic acids, minerals, peptides and plant-derived compounds.
The cancer biologist sees molecules capable of interacting with cellular signalling.
The clinician may see an adjunct that can reduce severe oral mucositis, ease pain and help reduce interruptions to radiotherapy.
One substance. Different scales of life.
And once again the boundaries we draw begin to disappear.
Flower.
Bee.
Hive.
Cell.
Human.
The chemistry keeps moving.
And what chemistry reaches the hive depends, in part, on the living landscape available to the bees.
A hive is partly made from its landscape
This also changes how I think about habitat.
A bee landscape is not merely acres of flowers measured in nectar and pollen.
The colony is gathering information and chemistry from many parts of the living world.
Flowers become nectar.
Pollen becomes protein.
Water enters cooling and metabolism.
Plant resins become propolis.
And the identity of those plants matters because propolis chemistry changes with geography, climate, season and botanical source. More than 800 compounds have been identified across different types of propolis, and one of the major challenges facing researchers is precisely that propolis from one landscape may be chemically different from propolis produced somewhere else.
That variability makes propolis harder to standardize.
But maybe the complexity is not something to strip away.
Maybe the way those compounds work together is part of what matters.
For much of modern drug development, natural products have been treated as starting material: identify an active compound, isolate it, purify it, standardize the dose, then develop that molecule or a defined combination into a drug.
But nature does not necessarily work one compound at a time.
Propolis arrives as a complex mixture of plant chemistry, and the relationships among those compounds may be part of what gives it its biological activity.
A review comparing whole propolis extracts with representative polyphenols specifically cautioned against attributing the activity of propolis solely to a handful of its best-known compounds.
Research on full-spectrum propolis has also found positive or synergistic interactions with several chemotherapy drugs, including enhanced antitumor activity and effects on chemoresistant cancer cells.
Maybe the lesson is not always to take apart what nature has already assembled. Maybe we should also be asking what the intact mixture is showing us.
Nature is not concerned with patents, products or profit margins. It gives the bee chemistry in combinations, and the bee carries that complexity home.
Perhaps there is something worth learning from that before we isolate the pieces, synthesize them and sell them back one molecule at a time.
So perhaps the question should not always be:
Which molecule can we pull out of this?
Perhaps sometimes it should also be:
What are these molecules doing together that we may lose when we pull them apart?
There is another part of this conversation that deserves to be said plainly.
Modern drug development depends heavily on substances that can be characterized, reproduced, manufactured consistently, quality-controlled and regulated.
The U.S. Food and Drug Administration itself describes botanical drugs as unusually complex because they can contain heterogeneous mixtures, uncertainty about active ingredients and substantial challenges in maintaining therapeutic consistency from batch to batch.
Patent law adds another wrinkle. U.S. patent guidance recognizes a “product of nature” exception for naturally occurring materials that do not possess markedly different characteristics from their natural counterparts.
A naturally occurring mixture that changes with plants, geography and season therefore does not fit the conventional commercial-development system as neatly as a defined compound, modified molecule, formulation, delivery system or specific use.
But nature is under no obligation to organize its chemistry around our patents, manufacturing lines or profit margins.
Nature is not trying to sell us one molecule at a time.
It is showing us relationships.
And bees may be carrying some of those relationships home.
There may even be an entourage effect at work, where the value lies partly in what the compounds do together, not simply in what each one does alone.
Pull them apart and study them individually, and we may learn a great deal about the pieces while missing something important about the whole.
Ecologically, that same complexity reveals something beautiful.
A piece of propolis contains a trace of place.
The plants surrounding a colony help determine the chemistry the bees are able to bring home.
The landscape is not merely outside the hive.
Some of it becomes the hive.
Maybe we have been standing too far away from nature
Humans are very good at imagining ourselves as observers.
We study the plant.
We study the bee.
We study cancer cells.
We study bacteria.
We study immune systems.
Then every once in a while, something like propolis exposes how artificial those divisions can be.
The molecules do not care which scientific department we assigned them to.
A flavonoid does not know whether we call its origin botany, entomology or medicine.
Life has been exchanging chemistry far longer than we have had names for any of it.
And perhaps that is the deeper lesson here.
We are not standing outside nature looking in.
Our cells use ancient molecular machinery shared across the history of life.
Apoptosis helps multicellular organisms control damaged cells.
Autophagy allows cells to recycle themselves in response to stress.
Plants manufacture molecules to survive their own biological struggles.
Bees encounter those molecules and weave them into colony defence.
Another defence exists within the bee herself.
Then another animal, us, discovers that some of this chemistry interacts with pathways inside our own cells.
The connection is not mystical.
It is more astonishing than that.
It is biological.
What the research does not yet tell us
Most of the anticancer evidence discussed here is still preclinical.
The animal research does not establish propolis as a proven treatment for human cancer, and the cell studies cannot tell us by themselves what will happen in a human body.
Propolis also differs enormously depending on plant source and geography. Extraction methods differ. Doses differ. Preparations differ.
Melittin has its own challenge. Its biological potency is part of what makes it scientifically interesting, but free melittin can also damage healthy cells, which is why so much current research is focused on targeted delivery systems.
Those are important scientific boundaries.
But they do not erase what has already been observed.
In living animal models, propolis has repeatedly produced measurable effects involving tumors, pathogens, inflammation, immunity and cellular pathways, including apoptosis and, in specific experimental contexts, autophagy.
In cell and animal research, melittin has likewise affected cancer-cell membranes, growth-factor signalling, migration, survival pathways and apoptosis.
The unanswered questions are not evidence that nothing is happening.
They are the reason the research continues.
Maybe the hive has been pointing outward all along
The longer I spend around bees, the harder it becomes to think of a colony as something separate from the world around it.
Follow the honey and you eventually find the flower.
Follow the pollen and you find a landscape.
Follow the propolis and you find the plants it came from.
Follow melittin and you enter the biology of the bee herself.
Follow either chemistry far enough and suddenly you are looking through a microscope at signalling pathways inside a mammalian cell.
That journey is almost absurd in its scale.
A bee leaves a dark colony and flies toward a resinous plant.
She returns carrying a fragment of that plant’s chemical world.
Other bees work it into the walls around them.
Inside those walls, thousands of insects live as a colony.
Inside the bee herself is another chemistry, evolved through another form of defence.
Years later, somewhere else entirely, scientists discover that molecules from both stories can interact with whether experimental cancer cells proliferate, whether blood vessels grow toward tumors, whether cancer cells migrate, whether pathogens survive, whether immune signals rise or fall, whether a cell enters autophagy, and whether another reaches apoptosis.
From plant.
To bee.
To hive.
To cell.
To us.
Perhaps connectedness with nature was never something we needed to invent.
Perhaps it was something we needed to notice.
Because every time a bee carries resin home, she brings back more than building material.
She brings home part of a plant’s defence.
And inside the bee herself is another defence whose chemistry is now being examined against some of the most difficult diseases humans face.
Hidden inside those small exchanges is a reminder that life has never existed as separate pieces.
The forest is in the hive.
The hive is in the landscape.
And we are still discovering how much of that same living chemistry reaches into us.
Forage Further: Research and Further Reading
- Therapeutic Potential of Propolis in Preclinical Models of Cancer and Infectious Diseases: A Review
International Journal of Molecular Sciences, 2025
Full paper
DOI: 10.3390/ijms26168041 - Thinking inside the box: Restoring the propolis envelope facilitates honey bee social immunity
PLOS ONE, 2024
Full paper
DOI: 10.1371/journal.pone.0291744 - Anticancer Activity of Propolis and Its Compounds
Nutrients, 2021
PubMed
DOI: 10.3390/nu13082594 - Anti-cancer activity of propolis extracts from stingless bees of Brunei Darussalam
Scientific Reports, 2026 collection
Full paper
DOI: 10.1038/s41598-025-32628-0 - Water-based propolis enhances 5-fluorouracil drug efficiency in gastric and colorectal cancer cells through cell stress response, anti-migratory, and apoptotic effects regardless of p53 status
Medical Oncology, 2025
PubMed
DOI: 10.1007/s12032-025-03023-6 - An Overview of the Evidence and Mechanism of Drug-Herb Interactions Between Propolis and Pharmaceutical Drugs
Frontiers in Pharmacology, 2022
Full paper
DOI: 10.3389/fphar.2022.876183 - Propolis Extract and Its Bioactive Compounds: From Traditional to Modern Extraction Technologies
Molecules, 2021
PubMed
DOI: 10.3390/molecules26102930 - Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer
npj Precision Oncology, 2020
PubMed
DOI: 10.1038/s41698-020-00129-0 - Melittin-Based Nanoparticles for Cancer Therapy: Mechanisms, Applications, and Future Perspectives
Pharmaceutics, 2025
Full paper
DOI: 10.3390/pharmaceutics17081019 - Venom-Derived Peptides in Breast Cancer: Pharmacological Mechanisms and Medicinal Chemistry-Guided Translational Development
Archiv der Pharmazie, 2026
PubMed
DOI: 10.1002/ardp.70320 - Exploiting the Potential of Propolis: A Multifaceted Approach to Applications and Sustainable Practices
Annals of African Medicine, 2026
PubMed
DOI: 10.4103/aam.aam_243_26 - What is a Botanical Drug?
U.S. Food and Drug Administration
FDA botanical drug information - Patent Subject Matter Eligibility: Products of Nature
United States Patent and Trademark Office
USPTO guidance - Standardized Apis mellifera propolis extract (EPP-AF®) reduces egg burden and granulomatous inflammation in experimental Schistosoma mansoni infection.
https://pmc.ncbi.nlm.nih.gov/articles/PMC13610971/ - Time- and Dose-Resolved DIA-PASEF Proteomics Maps the Transition from Adaptive Stress to Apoptotic Collapse in Melittin-Treated MDA-MB-231 Cells
https://pubmed.ncbi.nlm.nih.gov/42695876/ - A Review on Antiproliferative and Apoptotic Activities of Natural Honey
Anti-Cancer Agents in Medicinal Chemistry, 2015
PubMed: PubMed
DOI: 10.2174/1871520614666140722084747 - Honey as a Potential Natural Anticancer Agent: A Review of Its Mechanisms
Evidence-Based Complementary and Alternative Medicine, 2013
Full paper: PubMed Central
DOI: 10.1155/2013/829070 - Honey and cancer: from traditional medicine to modern adjuvant therapy
Frontiers in Oncology, 2026
PubMed: PubMed
Full paper: Frontiers in Oncology
DOI: 10.3389/fonc.2026.1745285 Fortified Chestnut Honey Triggers Apoptosis in Colon Cancer Cells
Plant Foods for Human Nutrition, 2026
PubMed: https://pubmed.ncbi.nlm.nih.gov/41964874/
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13070085/
DOI: https://link.springer.com/article/10.1007/s11130-026-01495-z
- Honey for managing oral mucositis induced by cancer therapies: An overview of systematic reviews
Complementary Therapies in Medicine, 2025
PubMed: PubMed
DOI: 10.1016/j.ctim.2025.103197

